

Daniel Lindholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8868844/publications.pdf>

Version: 2024-02-01

28
papers

1,460
citations

430874

18
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2738
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
2	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	2.2	171
3	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
4	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
5	Clinical and Genetic Determinants of Varicose Veins. <i>Circulation</i> , 2018, 138, 2869-2880.	1.6	98
6	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
7	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	4.1	75
8	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2018, 3, 1160.	6.1	57
9	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	3.9	56
10	Early diagnosis of acute coronary syndrome. <i>European Heart Journal</i> , 2017, 38, 3049-3055.	2.2	50
11	Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002162.	3.6	48
12	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. <i>American Heart Journal</i> , 2015, 169, 879-889.e7.	2.7	42
13	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1447-1456.	2.9	41
14	Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 881-887.	1.7	35
15	Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500,000 Individuals From the General Population. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	31
16	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
17	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 573-584.	3.2	26
18	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21

#	ARTICLE	IF	CITATIONS
19	Timing of percutaneous coronary intervention in patients with non-ST-elevation myocardial infarction: a SWEDEHEART study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 53-60.	4.0	18
20	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
21	Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR). <i>European Heart Journal</i> , 2019, 40, 2607-2615.	2.2	17
22	Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007381.	3.9	16
23	Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. <i>Heart</i> , 2019, 105, heartjnl-2018-314590.	2.9	12
24	Design and rationale of TROCADERO: A TRIal Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. <i>American Heart Journal</i> , 2015, 170, 465-470.	2.7	11
25	Bioresorbable Stents in PCI. <i>Current Cardiology Reports</i> , 2016, 18, 74.	2.9	9
26	Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. <i>EuroIntervention</i> , 2018, 14, e562-e569.	3.2	5
27	New Method for Assessing the Effect of Driving Distance to Hospital Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	4
28	Caffeine and incidence of dyspnea in patients treated with ticagrelor. <i>American Heart Journal</i> , 2018, 200, 141-143.	2.7	4